Here are the Dietary Docosahexaenoic Acid-Rich Supplementation Decreases Neurotoxic Lipid Mediators in Participants with Type 2 Diabetes and Neuropathic Pain journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Docosahexaenoic acid essential fatty acid, docosahexaenoic acid oral capsule, docosahexaenoic acid ethyl ester, docosahexaenoic acid dha po, docosahexaenoic acid dha supplements, bioactive metabolites of docosahexaenoic acid, dha docosahexaenoic acid health benefits, what is docosahexaenoic acid epa, docosahexaenoic acid common name.
Dietary Docosahexaenoic Acid-Rich Supplementation Decreases Neurotoxic Lipid Mediators in Participants with Type 2 Diabetes and Neuropathic Pain
Background/Objectives: There is increasing evidence linking circulating neurotoxic lipids to the progression of chronic neuroinflammatory diseases in the peripheral and central nervous systems. Strategies to modify lipid profiles, such as docosahexaenoic acid (DHA)-rich supplementation, may aid in managing conditions like painful diabetic neuropathy (pDN). In a previous study, we demonstrated that three months of DHA supplementation significantly altered the metabolomic profile of patients with painful diabetic neuropathy (pDN), resulting in symptom improvement. This study investigates whether DHA-rich supplementation reduces neurotoxic lipid mediators associated with pDN in individuals with type 2 diabetes mellitus (T2DM).
Methods: Forty individuals with type 2 diabetes participated in the "En Balance-PLUS" study, attending weekly lifestyle and nutrition education sessions while receiving daily supplementation of 1000 mg DHA and 200 mg EPA. Pain l evels were assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ) at baseline and after three months. Blood serum samples collected at these time points underwent untargeted lipidomic analyses, with ELISA used to evaluate biomarkers of necrosis (MLKL), autophagy (ATG5), and lipid chaperone protein (FABP5).
Results: Untargeted lipidomic analysis revealed that several neurotoxic-associated lipids significantly decreased after DHA-rich supplementation. Also, circulating levels of MLKL were reduced, while protein levels of ATG5 and FABP5 significantly increased. Conclusions: The reduction of circulating neurotoxic lipids and increase in neuroprotective lipids following DHA-rich supplementation are consistent with the reported roles of omega-3 polyunsaturated fatty acids (PUFAs) in reducing adverse symptoms associated with neuroinflammatory diseases and painful neuropathy. © 2024 by the authors.
Authors : Durán A.M.; Zamora F.; De León M.
Source : Multidisciplinary Digital Publishing Institute (MDPI)
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.3390/nu16234025 |
| ISSN | 20726643 |
| Volume | 16 |
You can download the article here
If You have any problem, contact us here